We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App

Nanopore Sequencing Cuts Tumor Analysis Times and Costs, Finds Study

By LabMedica International staff writers
Posted on 11 Dec 2023
Print article
Image: Nanopore sequencing makes analysis of copy number variations quicker, cheaper, and less complex (Photo courtesy of Oxford Nanopore)
Image: Nanopore sequencing makes analysis of copy number variations quicker, cheaper, and less complex (Photo courtesy of Oxford Nanopore)

Copy number variations (CNVs), which activate oncogenes and inactivate tumor suppressor genes, play a crucial role in the development and progression of cancers. As such, CNV analysis is a vital component of tumor grading and diagnosis. Traditionally, this analysis relies on nucleotide hybridization and next-generation sequencing, methods confined to high-complexity centralized laboratories and requiring several days to complete. A more rapid, cost-effective, and straightforward approach to CNV analysis could significantly enhance clinical decision-making, refine surgical planning, and facilitate the identification of potential molecular therapies within the timeframe of surgical procedures. Researchers have now identified nanopore sequencing as a method to refine CNV analysis.

A study conducted by researchers at Dartmouth-Hitchcock Medical Center (DHMC, Lebanon, NH, USA) has found nanopore sequencing to be a more efficient means for CNV analysis. They used Oxford Nanopore’s MinION device, which offers real-time interpretation of long-read nucleotide sequences. To adapt this technology for CNV detection, the team employed a technique involving the random analysis of linked DNA fragments, which allows for the identification of multiple mappable DNA fragments within a single sequencing read.

The study involved analyzing 26 malignant brain tumors using this method. The nanopore sequencing approach successfully detected the same genomic alterations and amplifications as those identified through clinically validated next-generation sequencing and chromosomal microarray analyses. This method also concurrently facilitates tumor methylation classification without necessitating additional tissue preparation, as promoter hypomethylation was observed in all detected amplified oncogenes. A patent application for this novel approach, named irreversible Sticking Compatible Overhang to Reconstruct DNA (iSCORED), is currently pending. The researchers view this accelerated method of CNV analysis as a significant step forward in reducing the time required to identify patients who could benefit from treatment with molecular-targeted therapies.

“The low cost per sample, a mere USD 125, and the ease of setting up the infrastructure with a budget of USD 6,000-8,000 for MinION and USD 14,000-16,000 for PromethION make it an economical option for clinical applications,” stated the researchers. “The unmatched turnaround time of 120-140 minutes further positions our method as a robust and invaluable tool for widespread implementation in clinical settings.”

Related Links:
Oxford Nanopore

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
POCT Fluorescent Immunoassay Analyzer
Gold Member
Hemoglobin Testing System

Print article


Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The HelioLiver Dx test has met the coprimary and secondary study endpoints in the CLiMB trial (Photo courtesy of Helio Genomics)

Blood-Based Test Outperforms Ultrasound in Early Liver Cancer Detection

Patients with liver cirrhosis and chronic hepatitis B are at a higher risk for developing hepatocellular carcinoma (HCC), the most prevalent type of liver cancer. The American Association for the Study... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The POC PCR test shortens time for STI test results (Photo courtesy of Visby Medical)

POC STI Test Shortens Time from ED Arrival to Test Results

In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2.5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics... Read more


view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.